David Loew (Ipsen)
Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap
You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal.
The French biotech, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
